Yourgene Health PLC Share option awards (7857L)
15 September 2021 - 4:00PM
UK Regulatory
TIDMYGEN
RNS Number : 7857L
Yourgene Health PLC
15 September 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Share option awards
Manchester, UK - 15 September 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces an award of
share options.
Award of options
The Company has today issued 1,160,000 options over Ordinary
Shares of 0.1p under the Company's Enterprise Management Incentive
(EMI) and unapproved share option schemes to a number of
individuals in the UK and international subsidiaries.
The options are exercisable in three tranches over three
financial years and are subject to certain performance conditions.
The options awarded are exercisable up to 14 September 2031, at a
price of 15 pence per share representing an approximation of the 30
day average share price.
Following the award of these new options, and taking into
account lapsed options, the Company has 59,459,172 shares under its
market-based and performance-based option schemes.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genomic services and
technologies. The Group works in partnership with global leaders in
DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and infectious diseases.
The Group's flagship in vitro diagnostic products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other
genetic disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests and DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation
platforms, powered by Ranger(R) Technology, the Yourgene
LightBench(R) and Yourgene QS250, ideal for cell-free DNA
applications in NIPT and oncology including liquid biopsy.
Yourgene Genomic Services is a global laboratory service network
equipped to be a full life-cycle partner for clinical, research and
pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop,
manufacture, obtain regulatory approval and commercialise new
products and services. In addition, Yourgene Genomic Services
offers an NIPT and high throughput COVID testing service.
Yourgene Health is headquartered in Manchester, UK with
facilities in Taipei, Singapore, the US and Canada, and is listed
on the London Stock Exchange's AIM market under the ticker "YGEN".
Follow us on LinkedIn and Twitter . Further information is
available at www.yourgene-health.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUQPBUPGPGC
(END) Dow Jones Newswires
September 15, 2021 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024